GB201317622D0 - Cancer biomarkers and uses thereof - Google Patents

Cancer biomarkers and uses thereof

Info

Publication number
GB201317622D0
GB201317622D0 GBGB1317622.7A GB201317622A GB201317622D0 GB 201317622 D0 GB201317622 D0 GB 201317622D0 GB 201317622 A GB201317622 A GB 201317622A GB 201317622 D0 GB201317622 D0 GB 201317622D0
Authority
GB
United Kingdom
Prior art keywords
cancer biomarkers
biomarkers
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1317622.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STAR BIOTECHNOLOGY Ltd F
F Star Biotechnology Ltd
Original Assignee
STAR BIOTECHNOLOGY Ltd F
F Star Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by STAR BIOTECHNOLOGY Ltd F, F Star Biotechnology Ltd filed Critical STAR BIOTECHNOLOGY Ltd F
Priority to GBGB1317622.7A priority Critical patent/GB201317622D0/en
Publication of GB201317622D0 publication Critical patent/GB201317622D0/en
Priority to JP2016546183A priority patent/JP6449308B2/ja
Priority to CA2925186A priority patent/CA2925186A1/en
Priority to HRP20181566TT priority patent/HRP20181566T1/hr
Priority to EA201690450A priority patent/EA201690450A1/ru
Priority to KR1020167011055A priority patent/KR20160092992A/ko
Priority to PE2016000450A priority patent/PE20160950A1/es
Priority to SG11201602605TA priority patent/SG11201602605TA/en
Priority to ES14781645.8T priority patent/ES2687783T3/es
Priority to BR112016007348A priority patent/BR112016007348A2/pt
Priority to CN201480055024.5A priority patent/CN105722997A/zh
Priority to EP14781645.8A priority patent/EP3052647B1/en
Priority to DK14781645.8T priority patent/DK3052647T3/en
Priority to LTEP14781645.8T priority patent/LT3052647T/lt
Priority to MX2016004286A priority patent/MX2016004286A/es
Priority to PCT/GB2014/052994 priority patent/WO2015049537A1/en
Priority to HK16109856.6A priority patent/HK1221746B/en
Priority to AU2014330942A priority patent/AU2014330942A1/en
Priority to IL244510A priority patent/IL244510A0/en
Priority to US15/087,272 priority patent/US20160289336A1/en
Priority to CL2016000777A priority patent/CL2016000777A1/es
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GBGB1317622.7A 2013-10-04 2013-10-04 Cancer biomarkers and uses thereof Ceased GB201317622D0 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
GBGB1317622.7A GB201317622D0 (en) 2013-10-04 2013-10-04 Cancer biomarkers and uses thereof
AU2014330942A AU2014330942A1 (en) 2013-10-04 2014-10-03 Cancer biomarkers and uses thereof
CN201480055024.5A CN105722997A (zh) 2013-10-04 2014-10-03 癌症生物标记物及其应用
DK14781645.8T DK3052647T3 (en) 2013-10-04 2014-10-03 BIOMARKERS FOR CANCER AND APPLICATIONS THEREOF
HRP20181566TT HRP20181566T1 (hr) 2013-10-04 2014-10-03 Biomarkeri raka i njihove uporabe
EA201690450A EA201690450A1 (ru) 2013-10-04 2014-10-03 Биомаркеры рака и их применения
KR1020167011055A KR20160092992A (ko) 2013-10-04 2014-10-03 암 바이오마커 및 이의 용도
PE2016000450A PE20160950A1 (es) 2013-10-04 2014-10-03 Biomarcadores de cancer y usos de los mismos
SG11201602605TA SG11201602605TA (en) 2013-10-04 2014-10-03 Cancer biomarkers and uses thereof
ES14781645.8T ES2687783T3 (es) 2013-10-04 2014-10-03 Biomarcadores de cáncer y usos de los mismos
BR112016007348A BR112016007348A2 (pt) 2013-10-04 2014-10-03 membro de ligação específica que se liga ao receptor do fator de crescimento epidérmico humano 2 (her2) para uso em um método de tratamento do câncer em um paciente, método de tratamento de câncer em um paciente, método de identificação de um câncer em um paciente, método para prognosticar a resposta de um câncer
JP2016546183A JP6449308B2 (ja) 2013-10-04 2014-10-03 がんバイオマーカー及びその使用
EP14781645.8A EP3052647B1 (en) 2013-10-04 2014-10-03 Cancer biomarkers and uses thereof
CA2925186A CA2925186A1 (en) 2013-10-04 2014-10-03 Cancer biomarkers and uses thereof
LTEP14781645.8T LT3052647T (lt) 2013-10-04 2014-10-03 Vėžio biožymenys ir jų panaudojimas
MX2016004286A MX2016004286A (es) 2013-10-04 2014-10-03 Biomarcadores de cancer y usos de los mismos.
PCT/GB2014/052994 WO2015049537A1 (en) 2013-10-04 2014-10-03 Cancer biomarkers and uses thereof
HK16109856.6A HK1221746B (en) 2013-10-04 2014-10-03 Cancer biomarkers and uses thereof
IL244510A IL244510A0 (en) 2013-10-04 2016-03-08 Cancer biomarkers and their uses
US15/087,272 US20160289336A1 (en) 2013-10-04 2016-03-31 Cancer biomarkers and uses thereof
CL2016000777A CL2016000777A1 (es) 2013-10-04 2016-04-04 Biomarcadores de cáncer y usos de los mismos

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1317622.7A GB201317622D0 (en) 2013-10-04 2013-10-04 Cancer biomarkers and uses thereof

Publications (1)

Publication Number Publication Date
GB201317622D0 true GB201317622D0 (en) 2013-11-20

Family

ID=49630223

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1317622.7A Ceased GB201317622D0 (en) 2013-10-04 2013-10-04 Cancer biomarkers and uses thereof

Country Status (20)

Country Link
US (1) US20160289336A1 (enExample)
EP (1) EP3052647B1 (enExample)
JP (1) JP6449308B2 (enExample)
KR (1) KR20160092992A (enExample)
CN (1) CN105722997A (enExample)
AU (1) AU2014330942A1 (enExample)
BR (1) BR112016007348A2 (enExample)
CA (1) CA2925186A1 (enExample)
CL (1) CL2016000777A1 (enExample)
DK (1) DK3052647T3 (enExample)
EA (1) EA201690450A1 (enExample)
ES (1) ES2687783T3 (enExample)
GB (1) GB201317622D0 (enExample)
HR (1) HRP20181566T1 (enExample)
IL (1) IL244510A0 (enExample)
LT (1) LT3052647T (enExample)
MX (1) MX2016004286A (enExample)
PE (1) PE20160950A1 (enExample)
SG (1) SG11201602605TA (enExample)
WO (1) WO2015049537A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006204459B2 (en) 2005-01-05 2012-11-01 F-Star Therapeutics Limited Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
JP5602625B2 (ja) 2007-06-26 2014-10-08 エフ−スター ビオテヒノロギッシェ フォルシュングス− ウント エントヴィッケルングスゲゼルシャフト ミット ベシュレンクテル ハフツング 結合物質のディスプレイ
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
TW201642897A (zh) * 2015-04-08 2016-12-16 Ｆ 星生物科技有限公司 Ｈｅｒ２結合劑治療
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11214618B2 (en) 2016-06-20 2022-01-04 F-Star Therapeutics Limited LAG-3 binding members
CN116640214A (zh) 2016-08-09 2023-08-25 科马布有限公司 分离抗体及其应用
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
CN107868814A (zh) * 2017-12-19 2018-04-03 威海威仕泰医疗科技有限公司 一种用于检测HER2基因的Dig标记探针的制备方法
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
CR20250022A (es) * 2018-04-02 2025-02-25 Bristol Myers Squibb Co Anticuerpos anti-trem-1, ácidos nucleicos y vectores de los mismos (divisional 2020-0450)
AU2019269641A1 (en) * 2018-05-17 2020-12-03 Immunome, Inc. CH3 domain epitope tags
CN108875302B (zh) * 2018-06-22 2022-02-22 广州漫瑞生物信息技术有限公司 一种检测细胞游离肿瘤基因拷贝数变异的系统和方法
CN112423845B (zh) 2018-07-12 2024-07-30 F-星治疗有限公司 结合pd-l1和cd137的抗体分子
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
CA3106048A1 (en) 2018-07-12 2020-01-16 F-Star Beta Limited Antibody molecules that bind cd137 and ox40
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
KR102325731B1 (ko) * 2020-01-15 2021-11-15 주식회사 베르티스 암의 진단용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006204459B2 (en) * 2005-01-05 2012-11-01 F-Star Therapeutics Limited Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
JP5602625B2 (ja) * 2007-06-26 2014-10-08 エフ−スター ビオテヒノロギッシェ フォルシュングス− ウント エントヴィッケルングスゲゼルシャフト ミット ベシュレンクテル ハフツング 結合物質のディスプレイ
EP2113255A1 (en) * 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
SG10201507044PA (en) * 2009-05-29 2015-10-29 Hoffmann La Roche Modulators for her2 signaling in her2 expressing patients with gastric cancer
EP2407487A1 (en) * 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody

Also Published As

Publication number Publication date
CA2925186A1 (en) 2015-04-09
CL2016000777A1 (es) 2017-02-17
BR112016007348A2 (pt) 2018-01-23
LT3052647T (lt) 2018-10-25
AU2014330942A1 (en) 2016-05-19
EP3052647B1 (en) 2018-07-11
KR20160092992A (ko) 2016-08-05
JP6449308B2 (ja) 2019-01-09
WO2015049537A1 (en) 2015-04-09
CN105722997A (zh) 2016-06-29
EP3052647A1 (en) 2016-08-10
IL244510A0 (en) 2016-04-21
HK1221746A1 (en) 2017-06-09
US20160289336A1 (en) 2016-10-06
EA201690450A1 (ru) 2016-10-31
ES2687783T3 (es) 2018-10-29
DK3052647T3 (en) 2018-10-22
MX2016004286A (es) 2017-01-18
HRP20181566T1 (hr) 2018-11-30
PE20160950A1 (es) 2016-10-02
SG11201602605TA (en) 2016-04-28
JP2016533395A (ja) 2016-10-27

Similar Documents

Publication Publication Date Title
IL244510A0 (en) Cancer biomarkers and their uses
GB2546662B (en) Antenna assembly and related methods
EP2971174A4 (en) Cancer biomarkers and classifiers and uses thereof
HRP20201701T8 (hr) Aril eteri i njihove uporabe
ZA201505735B (en) Cancer drug and uses
IL246067A0 (en) Classification of prostate cancer
SG11201510282PA (en) Sepsis biomarkers and uses thereof
GB201321474D0 (en) Novel biomarkers
EP3066217A4 (en) Cancer biomarkers and classifiers and uses thereof
GB201306147D0 (en) Novel biomarker signature and uses thereof
GB201322800D0 (en) Prostate cancer biomarkers
GB201316524D0 (en) Biomarkers
IL244632A0 (en) Cancer biomarker and diagnostics
GB201309426D0 (en) Biomarkers
SG11201601234TA (en) Circulating cancer biomarker and its use
GB201320992D0 (en) Complex and uses thereof
GB201316526D0 (en) Biomarkers
GB201308077D0 (en) Biomarkers
ZA201601880B (en) Hetero-transglycosylase and uses thereof
EP3015476A4 (en) Tumor biomarker
GB201312638D0 (en) Biomarkers
GB201304460D0 (en) Biomarker
GB201306394D0 (en) Cancer biomarker
GB201322783D0 (en) Biomarkers
GB201308639D0 (en) Biomarkers and uses of thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)